121 related articles for article (PubMed ID: 30061246)
1. Diagnostic Utility of Prostein, Uroplakin II and SATB2 for Diagnosing Carcinoma of Unknown Primary Origin: A Systematic Immunohistochemical Profiling.
Mochizuki K; Kawai M; Odate T; Tahara I; Inoue T; Kasai K; Nakazawa T; Katoh R; Kondo T
Anticancer Res; 2018 Aug; 38(8):4759-4766. PubMed ID: 30061246
[TBL] [Abstract][Full Text] [Related]
2. Utility of uroplakin II expression as a marker of urothelial carcinoma.
Tian W; Guner G; Miyamoto H; Cimino-Mathews A; Gonzalez-Roibon N; Argani P; Li X; Sharma R; Subhawong AP; Rezaei K; Bivalacqua TJ; Epstein JI; Bishop JA; Netto GJ
Hum Pathol; 2015 Jan; 46(1):58-64. PubMed ID: 25449628
[TBL] [Abstract][Full Text] [Related]
3. Role of SATB2 in distinguishing the site of origin in glandular lesions of the bladder/urinary tract.
Giannico GA; Gown AM; Epstein JI; Revetta F; Bishop JA
Hum Pathol; 2017 Sep; 67():152-159. PubMed ID: 28711650
[TBL] [Abstract][Full Text] [Related]
4. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical Differentiation of Plasmacytoid Urothelial Carcinoma From Secondary Carcinoma Involvement of the Bladder.
Borhan WM; Cimino-Mathews AM; Montgomery EA; Epstein JI
Am J Surg Pathol; 2017 Nov; 41(11):1570-1575. PubMed ID: 28786878
[TBL] [Abstract][Full Text] [Related]
6. Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung.
Chang A; Amin A; Gabrielson E; Illei P; Roden RB; Sharma R; Epstein JI
Am J Surg Pathol; 2012 Oct; 36(10):1472-6. PubMed ID: 22982890
[TBL] [Abstract][Full Text] [Related]
7. Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants.
Li W; Liang Y; Deavers MT; Kamat AM; Matin SF; Dinney CP; Czerniak B; Guo CC
Am J Clin Pathol; 2014 Dec; 142(6):864-71. PubMed ID: 25389341
[TBL] [Abstract][Full Text] [Related]
8. A combination of p40, GATA-3 and uroplakin II shows utility in the diagnosis and prognosis of muscle-invasive urothelial carcinoma.
Leivo MZ; Elson PJ; Tacha DE; Delahunt B; Hansel DE
Pathology; 2016 Oct; 48(6):543-9. PubMed ID: 27594510
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic utility of immunohistochemical marker prostein for evaluation of primary and metastatic prostatic carcinomas.
Garudadri G; Rao BV; Sundaram C; Fonseca D; Murthy SS; Sharma R; Rao TS
Indian J Pathol Microbiol; 2020 Feb; 63(Supplement):S18-S24. PubMed ID: 32108621
[TBL] [Abstract][Full Text] [Related]
10. A newly developed uroplakin II antibody with increased sensitivity in urothelial carcinoma of the bladder.
Hoang LL; Tacha DE; Qi W; Yu C; Bremer RE; Chu J; Haas TS; Cheng L
Arch Pathol Lab Med; 2014 Jul; 138(7):943-9. PubMed ID: 24978921
[TBL] [Abstract][Full Text] [Related]
11. Mining The Cancer Genome Atlas gene expression data for lineage markers in distinguishing bladder urothelial carcinoma and prostate adenocarcinoma.
Ch'ng ES
Sci Rep; 2021 Mar; 11(1):6765. PubMed ID: 33762601
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder.
Lane Z; Hansel DE; Epstein JI
Am J Surg Pathol; 2008 Sep; 32(9):1322-6. PubMed ID: 18670358
[TBL] [Abstract][Full Text] [Related]
13. Prostein expression in human tumors: a tissue microarray study on 19,202 tumors from 152 different Tumor entities.
Viehweger F; Böcker C; Weidemann S; Freytag M; Menz A; Büscheck F; Luebke AM; Putri D; Kluth M; Hube-Magg C; Hinsch A; Lennartz M; Lutz F; Reiswich V; Höflmayer D; Fraune C; Möller K; Bernreuther C; Lebok P; Sauter G; Steurer S; Dum D; Marx AH; Simon R; Krech T; Clauditz TS; Jacobsen F; Gorbokon N; Burandt E; Minner S; Kind S
Diagn Pathol; 2024 Jan; 19(1):12. PubMed ID: 38218896
[TBL] [Abstract][Full Text] [Related]
14. SATB2 is a supplementary immunohistochemical marker to CDX2 in the diagnosis of colorectal carcinoma metastasis in an unknown primary.
Dabir PD; Svanholm H; Christiansen JJ
APMIS; 2018 Jun; 126(6):494-500. PubMed ID: 29924451
[TBL] [Abstract][Full Text] [Related]
15. Clinical utility of immunohistochemistry in the diagnoses of urinary bladder neoplasia.
Hodges KB; Lopez-Beltran A; Emerson RE; Montironi R; Cheng L
Appl Immunohistochem Mol Morphol; 2010 Oct; 18(5):401-10. PubMed ID: 20505509
[TBL] [Abstract][Full Text] [Related]
16. SATB2 as an Immunohistochemical Marker for Colorectal Adenocarcinoma: A Concise Review of Benefits and Pitfalls.
Berg KB; Schaeffer DF
Arch Pathol Lab Med; 2017 Oct; 141(10):1428-1433. PubMed ID: 28968158
[TBL] [Abstract][Full Text] [Related]
17. Utility of p63 immunohistochemical stain in differentiating urothelial carcinomas from adenocarcinomas of prostate.
Ud Din N; Qureshi A; Mansoor S
Indian J Pathol Microbiol; 2011; 54(1):59-62. PubMed ID: 21393879
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Antibodies to Detect Uroplakin in Urothelial Carcinomas.
Kristoffersen HL; Røge R; Nielsen S
Appl Immunohistochem Mol Morphol; 2022 May-Jun 01; 30(5):326-332. PubMed ID: 35510771
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
[TBL] [Abstract][Full Text] [Related]
20. GATA3 Positivity in Benign Radiated Prostate Glands: A Potential Diagnostic Pitfall.
Wobker SE; Khararjian A; Epstein JI
Am J Surg Pathol; 2017 Apr; 41(4):557-563. PubMed ID: 28291125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
